# EDGAR Filing Document

**Accession Number:** 0001958777
**File Stem:** 0001493152-26-013347
**Filing Date:** 2026-3
**Character Count:** 2289
**Document Hash:** 85d33975b6c8fc460ec8c304089b03e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-013347.hdr.sgml**: 20260501

**ACCESSION NUMBER**: 0001493152-26-013347

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FibroBiologics, Inc.
- **CENTRAL INDEX KEY:** 0001958777
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863329066
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 9350 KIRBY DRIVE
- **STREET 2:** SUITE 300
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054
- **BUSINESS PHONE:** 281-671-5150

**MAIL ADDRESS:**
- **STREET 1:** 9350 KIRBY DRIVE
- **STREET 2:** SUITE 300
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FibroBiologics Inc.
- **DATE OF NAME CHANGE:** 20221216

**FIBROBIOLOGICS, INC.**

455 E. Medical Center Blvd.

Suite 300

Houston, Texas 77598

March 27, 2026

**<u>VIA EDGAR</u>**

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **RE:** | **FibroBiologics, Inc. (the "Company")** |
|  | **Registration Statement on Form S-1** |
|  | **Filed March 27, 2026** |
|  | **File No. 333-294713** |

---

Ladies and Gentlemen:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-294713) be accelerated by the Securities and Exchange Commission to 5:15 P.M. (Eastern Time) on March 31, 2026, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.

We request that we be notified of such effectiveness by a telephone call to Barrett S. DiPaolo of Sichenzia Ross Ference LLP at 646-810-2173, and that such effectiveness also be confirmed in writing.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| FibroBiologics, Inc. | FibroBiologics, Inc. |
| By: | */s/ Ruben A. Garcia* |
| Name: | Ruben A. Garcia |
| Title: | General Counsel |

---